US FDA finally ready to start supply chain pilot
This article was originally published in SRA
More than four years ago, the US Food and Drug Administration said it was launching a new program aimed allowing the agency to focus its resources on drugs brought into the US that pose the greatest risks to consumers, while expediting the entry of specific finished medicines and active pharmaceutical ingredients (APIs) that meet certain criteria.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.